S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
Log in
NYSE:MNK

Mallinckrodt Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$0.33
-0.03 (-8.33 %)
(As of 03/5/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.30
Now: $0.33
$0.36
50-Day Range
$0.14
MA: $0.34
$0.75
52-Week Range
$0.75
Now: $0.33
$6.42
Volume687,491 shs
Average Volume6.49 million shs
Market Capitalization$27.91 million
P/E RatioN/A
Dividend YieldN/A
Beta3.06
Mallinckrodt Plc is a global specialty pharmaceuticals company. It develops, manufactures, markets and distributes both branded and generic specialty pharmaceutical products and medical imaging agents. It operates through the Specialty Brands and Specialty Generics segments. The Specialty Brands segment includes branded medicines. The Specialty Generics segment relates to specialty generic drugs, active pharmaceutical ingredients, as well as external manufacturing. The company was founded by Gustavo Mallinckrodt, Otto Mallinckrodt and Edward Mallinckrodt in 1867 and is headquartered in Blanchardstown, Dublin.
Mallinckrodt logo

Headlines

See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone(531) 696-0000
Employees3,400
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.16 billion
Cash Flow$6.60 per share
Book Value$23.08 per share

Profitability

Net Income$-996,500,000.00

Miscellaneous

Market Cap$27.91 million
Next Earnings DateN/A
OptionableOptionable

MarketRank

Overall MarketRank

1.72 out of 5 stars

Medical Sector

214th out of 1,969 stocks

Pharmaceutical Preparations Industry

96th out of 771 stocks

Analyst Opinion: 2.8Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 1.9 5 -4 -3 -2 -1 -

Receive MNK News and Ratings via Email

Sign-up to receive the latest news and ratings for MNK and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Mallinckrodt (NYSE:MNK) Frequently Asked Questions

Is Mallinckrodt a buy right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mallinckrodt in the last twelve months. There are currently 3 sell ratings and 5 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Mallinckrodt stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MNK, but not buy additional shares or sell existing shares.
View analyst ratings for Mallinckrodt
or view top-rated stocks.

What stocks does MarketBeat like better than Mallinckrodt?

Wall Street analysts have given Mallinckrodt a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Mallinckrodt wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were Mallinckrodt's earnings last quarter?

Mallinckrodt plc (NYSE:MNK) released its earnings results on Tuesday, August, 4th. The company reported $1.89 earnings per share for the quarter, topping analysts' consensus estimates of $1.34 by $0.55. The company had revenue of $700.90 million for the quarter, compared to analyst estimates of $630.19 million. Mallinckrodt had a positive trailing twelve-month return on equity of 34.26% and a negative net margin of 89.94%. The firm's revenue was down 14.9% compared to the same quarter last year. During the same quarter last year, the firm earned $2.53 EPS.
View Mallinckrodt's earnings history
.

What price target have analysts set for MNK?

8 equities research analysts have issued 1-year price objectives for Mallinckrodt's stock. Their forecasts range from $1.50 to $4.00. On average, they expect Mallinckrodt's stock price to reach $2.63 in the next twelve months. This suggests a possible upside of 695.5% from the stock's current price.
View analysts' price targets for Mallinckrodt
or view top-rated stocks among Wall Street analysts.

Who are Mallinckrodt's key executives?

Mallinckrodt's management team includes the following people:
  • Mark C. Trudeau, President, Chief Executive Officer & Director
  • Bryan M. Reasons, Chief Financial Officer & Executive Vice President
  • Steven Joseph Romano, Chief Scientific Officer & Executive VP
  • Babatunde Adekunle Otulana, Chief Medical Officer & Senior Vice President
  • Michele Robertson, Chief Compliance Officer & Senior Vice President

Who are some of Mallinckrodt's key competitors?

What other stocks do shareholders of Mallinckrodt own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Mallinckrodt investors own include Gilead Sciences (GILD), Micron Technology (MU), Bausch Health Companies (BHC), Endo International (ENDP), Teva Pharmaceutical Industries (TEVA), Gerdau (GGB), AT&T (T), Alibaba Group (BABA), (CELG) and Advanced Micro Devices (AMD).

What is Mallinckrodt's stock symbol?

Mallinckrodt trades on the New York Stock Exchange (NYSE) under the ticker symbol "MNK."

Who are Mallinckrodt's major shareholders?

Mallinckrodt's stock is owned by a variety of retail and institutional investors. Top institutional investors include KBC Group NV (1.34%) and Accredited Investors Inc. (0.36%). Company insiders that own Mallinckrodt stock include Bryan M Reasons and Mark Trudeau.
View institutional ownership trends for Mallinckrodt
.

Which institutional investors are buying Mallinckrodt stock?

MNK stock was purchased by a variety of institutional investors in the last quarter, including KBC Group NV, and Accredited Investors Inc.. Company insiders that have bought Mallinckrodt stock in the last two years include Bryan M Reasons, and Mark Trudeau.
View insider buying and selling activity for Mallinckrodt
or or view top insider-buying stocks.

What is Mallinckrodt's stock price today?

One share of MNK stock can currently be purchased for approximately $0.33.

How much money does Mallinckrodt make?

Mallinckrodt has a market capitalization of $27.91 million and generates $3.16 billion in revenue each year. The company earns $-996,500,000.00 in net income (profit) each year or $8.88 on an earnings per share basis.

How many employees does Mallinckrodt have?

Mallinckrodt employs 3,400 workers across the globe.

What is Mallinckrodt's official website?

The official website for Mallinckrodt is www.mallinckrodt.com.

Where are Mallinckrodt's headquarters?

Mallinckrodt is headquartered at COLLEGE BUSINESS & TECHNOLOGY PARK CRUISERATH BLANCHARDSTOWN, DUBLIN 15 L2, D15.

How can I contact Mallinckrodt?

Mallinckrodt's mailing address is COLLEGE BUSINESS & TECHNOLOGY PARK CRUISERATH BLANCHARDSTOWN, DUBLIN 15 L2, D15. The company can be reached via phone at (531) 696-0000 or via email at [email protected]


This page was last updated on 3/7/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.